Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon

Frontiers in Endocrinology

Endocrinology

Anna Zenno¹  Christian L. Roth² 

[1] Division of Endocrinology, Department of Pediatrics, University of Washington, Seattle, WA, United States;Seattle Children’s Research Institute, Department of Pediatrics, School of Medicine, University of Washington, Seattle, WA, United States;Division of Endocrinology, Department of Pediatrics, University of Washington, Seattle, WA, United States;

关键词: obesity;    brain tumor;    hypothalamic injury;    energy homeostasis;    drug intervention;   

DOI  :  10.3389/fendo.2023.1256514

 received in 2023-07-10, accepted in 2023-08-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

Hypothalamic obesity (HO) is a complex and rare disorder affecting multiple regulatory pathways of energy intake and expenditure in the brain as well as the regulation of the autonomic nervous system and peripheral hormonal signaling. It can be related to monogenic obesity syndromes which often affect the central leptin-melanocortin pathways or due to injury of the hypothalamus from pituitary and hypothalamic tumors, such as craniopharyngioma, surgery, trauma, or radiation to the hypothalamus. Traditional treatments of obesity, such as lifestyle intervention and specific diets, are still a therapeutic cornerstone, but often fail to result in meaningful and sustained reduction of body mass index. This review will give an update on pharmacotherapies of HO related to hypothalamic injury. Recent obesity drug developments are promising for successful obesity intervention outcomes.

【 授权许可】

Unknown   
Copyright © 2023 Roth and Zenno